A. Mantingh

Second‐trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome

J. M. M. van Lith, John J. Pratt, J. R. Beekhuis et al. · Prenatal Diagnosis · 1992 · 118 citations

NUCHAL TRANSLUCENCY CANNOT BE USED AS A SCREENING TEST FOR CHROMOSOMAL ABNORMALITIES IN THE FIRST TRIMESTER OF PREGNANCY IN A ROUTINE ULTRASOUND PRACTICE

Louise Kornman, L. P. Morssink, J. R. Beekhuis et al. · Prenatal Diagnosis · 1996 · 108 citations

Fetal Medicine, Diagnosis, Gynecology +21

Randomised controlled trial of magnetic-resonance pelvimetry in breech presentation at term

Aren J. van Loon, A. Mantingh, Elvira K. Serlier et al. · The Lancet · 1997 · 103 citations

Breech Presentation, Controlled Trial, Magnetic-resonance Pelvimetry +4

The influence of serum screening on the amniocentesis rate in women of advanced maternal age

J. R. Beekhuis, B. T. H. M. de Wolf, A. Mantingh et al. · Prenatal Diagnosis · 1994 · 92 citations

MATERNAL SERUM SCREENING FOR FETAL DOWN SYNDROME IN IVF PREGNANCIES

L. S. M. Ribbert, Louise Kornman, B. T. H. M. de Wolf et al. · Prenatal Diagnosis · 1996 · 80 citations

Down Syndrome, Infertility, Maternal Serum Hcg +14